Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
نویسندگان
چکیده
Type 2 diabetes mellitus (T2DM) continues to rise in prevalence in the United States and worldwide. Despite advances in medical treatments for T2DM, many patients remain uncontrolled. By targeting centrally mediated pathways of glucose metabolism, bromocriptine represents a novel therapeutic option in T2DM. Several small clinical trials demonstrate improvements in insulin resistance and glycemic control. After the submission of data from four recent, large clinical trials, the US Food and Drug Administration has approved the use of bromocriptine in T2DM. We review the available data from these four trials and other published studies. Bromocriptine is a promising therapy for diabetes patients and demonstrates modest improvements in glycemic control.
منابع مشابه
Concomitant use of Dopamine agonist Bromocriptine with Glimepride Improves Insulin Sensitivity in Type II Diabetic Patients
Type -2 diabetes mellitus (T2DM) is a complex syndrome originated by a multifactorial pathogenesis. Restoration of a normal glycaemia is very difficult and requires a multiple medication with different mechanismsof action that can be used in combination to produce an additive effect. Bromocriptine (BC) is a sympatholytic D2 dopamine agonist which can be used as an anti-diabetic agent with a nov...
متن کاملEffect of emotional intelligence in glycemic control in patients with type II diabetes
Diabetes, in addition to adverse physical effects, is associated with many psychological problems. The correlation between physical health and emotional intelligence are acceptable. The aim of this study was to determine the effect of emotional intelligence training in glycemic control in patients with type II diabetes. The present study was a quasi-experimental research, which was conducted in...
متن کاملTimed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus
BACKGROUND Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control may reduce long-term CVD risk. However, other risk factors such as elevated vascular sympathetic tone and/or endothelial dysfunction may be stronger potentiators of CVD. This study evaluated the impact of bromocriptine-QR...
متن کاملImpact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study
BACKGROUND The concurrent use of a postprandial insulin sensitizing agent, such as bromocriptine-QR, a quick release formulation of bromocriptine, a dopamine D2 receptor agonist, may offer a strategy to improve glycemic control and limit/reduce insulin requirement in type 2 diabetes (T2DM) patients on high-dose insulin. This open label pilot study evaluated this potential utility of bromocripti...
متن کاملپیش بینی عوامل موثر بر تبعیت دارویی و فعالیت جسمانی در بیماران دیابت نوع دو بر اساس نظریه رفتار برنامه ریزی شده
Background and Aim: Self-care has a vital role in the control and prevention of complications in patients with Type-2 diabetes mellitus (T2DM), two important behaviors in self-care being medication adherence and physical activity. Regular physical activity has been shown to improve glycemic control, reduce blood pressure, reduce lipids and improve cardiorespiratory fitness in individuals with T...
متن کامل